Treatment of Brugada Syndrome in 2023: Know Where You Come From to Know Where You Are Going.

HomeCirculationVol. 147, No. 21Treatment of Brugada Syndrome in 2023: Know Where You Come From to Know Where You Are Going No AccessEditorialRequest AccessFull TextAboutView Full TextView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toNo AccessEditorialRequest AccessFull TextTreatment of Brugada Syndrome in 2023: Know Where You Come From to Know Where You Are Going Sami Viskin and Raphael Rosso Sami ViskinSami Viskin Correspondence to: Sami Viskin, MD, Department of Cardiology, Tel Aviv Sourasky Medical Center, Weizman 6, Tel Aviv 64239, Israel. Email E-mail Address: [email protected] https://orcid.org/0000-0002-2623-5540 Department of Cardiology, Tel Aviv Sourasky Medical Center and Sackler School of Medicine, Tel Aviv University, Israel. Search for more papers by this author and Raphael RossoRaphael Rosso Department of Cardiology, Tel Aviv Sourasky Medical Center and Sackler School of Medicine, Tel Aviv University, Israel. Search for more papers by this author Originally published22 May 2023https://doi.org/10.1161/CIRCULATIONAHA.123.064673Circulation. 2023;147:1579–1581This article is a commentary on the followingLong-Term Outcomes of Brugada Substrate Ablation: A Report from BRAVO (Brugada Ablation of VF Substrate Ongoing Multicenter Registry)FootnotesCirculation is available at www.ahajournals.org/journal/circThe opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.For Disclosures, see page 1581.Correspondence to: Sami Viskin, MD, Department of Cardiology, Tel Aviv Sourasky Medical Center, Weizman 6, Tel Aviv 64239, Israel. Email [email protected]comReferences1. Nademanee K, Chung FP, Sacher F, Nogami A, Nakagawa H, Jiang C, Hocini M, Behr E, Veerakul G, Smit JJ, et al. Long-term outcomes of Brugada substrate ablation: a report from BRAVO (Brugada Ablation of VF Substrate Ongoing Multicenter Registry).Circulation. 2023; 147:1568–1578. doi: 10.1161/CIRCULATIONAHA.122.063367LinkGoogle Scholar2. Milman A, Andorin A, Gourraud JB, Sacher F, Mabo P, Kim SH, Maeda S, Takahashi Y, Kamakura T, Aiba T, et al. Age of first arrhythmic event in Brugada syndrome: data from the SABRUS (Survey on Arrhythmic Events in Brugada Syndrome) in 678 patients.Circ Arrhythm Electrophysiol. 2017; 10:e005222. doi: 10.1161/CIRCEP.117.005222LinkGoogle Scholar3. Adler A, Rosso R, Chorin E, Havakuk O, Antzelevitch C, Viskin S. Risk stratification in Brugada syndrome: clinical characteristics, electrocardiographic parameters, and auxiliary testing.Heart Rhythm. 2016; 13:299–310. doi: 10.1016/j.hrthm.2015.08.038CrossrefMedlineGoogle Scholar4. Ohgo T, Okamura H, Noda T, Satomi K, Suyama K, Kurita T, Aihara N, Kamakura S, Ohe T, Shimizu W. Acute and chronic management in patients with Brugada syndrome associated with electrical storm of ventricular fibrillation.Heart Rhythm. 2007; 4:695–700. doi: 10.1016/j.hrthm.2007.02.014CrossrefMedlineGoogle Scholar5. Haissaguerre M, Extramiana F, Hocini M, Cauchemez B, Jais P, Cabrera JA, Farre J, Leenhardt A, Sanders P, Scavee C, et al. Mapping and ablation of ventricular fibrillation associated with long-QT and Brugada syndromes.Circulation. 2003; 108:925–928. doi: 10.1161/01.CIR.0000088781.99943.95LinkGoogle Scholar6. Morita H, Zipes DP, Morita ST, Lopshire JC, Wu J. Epicardial ablation eliminates ventricular arrhythmias in an experimental model of Brugada syndrome.Heart Rhythm. 2009; 6:665–671. doi: 10.1016/j.hrthm.2009.01.007CrossrefMedlineGoogle Scholar7. Nademanee K, Veerakul G, Chandanamattha P, Chaothawee L, Ariyachaipanich A, Jirasirirojanakorn K, Likittanasombat K, Bhuripanyo K, Ngarmukos T. Prevention of ventricular fibrillation episodes in Brugada syndrome by catheter ablation over the anterior right ventricular outflow tract epicardium.Circulation. 2011; 123:1270–1279. doi: 10.1161/CIRCULATIONAHA.110.972612LinkGoogle Scholar8. Pappone C, Brugada J, Vicedomini G, Ciconte G, Manguso F, Saviano M, Vitale R, Cuko A, Giannelli L, Calovic Z, et al. Electrical substrate elimination in 135 consecutive patients with Brugada syndrome.Circ Arrhythm Electrophysiol. 2017; 10:e005053. doi: 10.1161/CIRCEP.117.005053LinkGoogle Scholar9. Belhassen B, Glick A, Viskin S. Efficacy of quinidine in high-risk patients with Brugada syndrome.Circulation. 2004; 110:1731–1737. doi: 10.1161/01.CIR.0000143159.30585.90LinkGoogle Scholar10. Miles C, Boukens BJ, Scrocco C, Wilde AA, Nademanee K, Haissaguerre M, Coronel R, Behr ER. Subepicardial cardiomyopathy: a disease underlying J-wave syndromes and idiopathic ventricular fibrillation.Circulation. In pressGoogle Scholar11. Nademanee K, Raju H, de Noronha SV, Papadakis M, Robinson L, Rothery S, Makita N, Kowase S, Boonmee N, Vitayakritsirikul V, et al. Fibrosis, connexin-43, and conduction abnormalities in the Brugada syndrome.J Am Coll Cardiol. 2015; 66:1976–1986. doi: 10.1016/j.jacc.2015.08.862CrossrefMedlineGoogle Scholar12. Viskin S, Rosso R, Friedensohn L, Havakuk O, Wilde AA. Everybody has Brugada syndrome until proven otherwise?.Heart Rhythm. 2015; 12:1595–1598. doi: 10.1016/j.hrthm.2015.04.017CrossrefMedlineGoogle Scholar13. Viskin S, Wilde AAM, Guevara-Valdivia ME, Daoulah A, Krahn A, Zipes DP, Halkin A, Shivkumar K, Boyle NG, Adler A, et al. Quinidine, a life-saving medication for Brugada syndrome, is inaccessible in many countries.J Am Coll Cardiol. 2013; 61:2383–2387. doi: 10.1016/j.jacc.2013.02.077CrossrefMedlineGoogle Scholar14. Viskin S. Radiofrequency ablation of asymptomatic Brugada syndrome: don’t go burning my heart.Circulation. 2018; 137:1883–1884. doi: 10.1161/CIRCULATIONAHA.117.032624LinkGoogle Scholar15. Probst V, Goronflot T, Anys S, Tixier R, Briand J, Berthome P, Geoffroy O, Clementy N, Mansourati J, Jesel L, et al. Robustness and relevance of predictive score in sudden cardiac death for patients with Brugada syndrome.Eur Heart J. 2021; 42:1687–1695. doi: 10.1093/eurheartj/ehaa763CrossrefMedlineGoogle Scholar eLetters(0)eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate.Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page.Sign In to Submit a Response to This Article Previous Back to top Next FiguresReferencesRelatedDetailsRelated articlesLong-Term Outcomes of Brugada Substrate Ablation: A Report from BRAVO (Brugada Ablation of VF Substrate Ongoing Multicenter Registry)Koonlawee Nademanee, et al. Circulation. 2023;147:1568-1578 May 23, 2023Vol 147, Issue 21 Advertisement Article InformationMetrics © 2023 American Heart Association, Inc.https://doi.org/10.1161/CIRCULATIONAHA.123.064673PMID: 37216435 Originally publishedMay 22, 2023 PDF download Advertisement SubjectsArrhythmiasCatheter Ablation and Implantable Cardioverter-DefibrillatorVentricular Fibrillation